Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337490 · ClinicalTrials.gov registry record · Phase 3
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
A Phase 3 study, sponsored by Mayne Pharma International Pty.
- Completed
- Registry status
- Phase 3
- Development phase
- 296
- Enrollment target
NCT03337490: Completed Phase 3 study, sponsored by Mayne Pharma International Pty.
NCT03337490 is a Phase 3 study that has completed, run by Mayne Pharma International Pty. The registered enrollment target is 296 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03337490, a Phase 3 study, has completed, sponsored by Mayne Pharma International Pty.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 296 participants
- Enrollment target
Study Summary
This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study.
Primary Outcome
The primary endpoint is the proportion of index subjects who are lice free at Day 15
Interventions
- DRUG Ivermectin 0.5% Topical Application Lotion
- DRUG Ivermectin 0.5% Topical Application Lotion [SKLICE]
- DRUG Placebo 0% Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 3 |
What the finished NCT03337490 record still lists
NCT03337490 is an interventional study that assigns participants to a tested intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Ivermectin 0.5% Topical Application Lotion is the first listed.
NCT03337490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03337490 about?
NCT03337490 is a clinical study titled "A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice". This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study.
What is the current status of trial NCT03337490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 296 participants. The study started on 2017-10-02. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT03337490?
The interventions under investigation include: Ivermectin 0.5% Topical Application Lotion (DRUG), Ivermectin 0.5% Topical Application Lotion [SKLICE] (DRUG), Placebo 0% Lotion (DRUG).
Who is sponsoring clinical trial NCT03337490?
This trial is sponsored by Mayne Pharma International Pty, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03337490's enrollment target sits among peer trials
296 1164th of 2000 higher than 835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
- NCT06828445 · 296 participants · Phase 1
Increasing Affordable Fruits and Vegetables for Families With Food Insecurity
- NCT06920563 · 296 participants · NA
Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI